EU/3/07/468: Orphan designation for the treatment of malaria

Dihydroartemisinin / piperaquine

Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2011 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 3 August 2007, orphan designation (EU/3/07/468) was granted by the European Commission to Sigma Tau Industrie Farmaceutiche Riunite S.p.A, Italy, for dihydroartemisinin, piperaquine for the treatment of malaria.

Key facts

Active substance
  • Dihydroartemisinin
  • piperaquine
Intended use
Treatment of malaria
Orphan designation status
EU designation number
Date of designation
Sigma Tau Industrie Farmaceutiche Riunite S.p.A
Viale Shakespeare 47
00144 Rome
Telephone: +39 06 91 39 36 57

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating